Cargando…
The construction of the novel magnetic prodrug Fe(3)O(4)@DOX and its antagonistic effects on hepatocarcinoma with low toxicity
Doxorubicin (DOX) is widely used as a chemotherapeutic agent for liver cancer. However, its clinical applications are greatly restricted by its nonselective cytotoxicity. A novel magnetic prodrug, Fe(3)O(4)@DOX, was designed, synthesized and characterized, and Fe(3)O(4) and DOX were connected by the...
Autores principales: | Li, Jun, Li, Liang, Lv, Yang, Zou, Hao, Wei, Yanping, Nie, Fei, Duan, Wanli, Sedike, Maidinamu, Xiao, Liang, Wang, Mei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9055880/ https://www.ncbi.nlm.nih.gov/pubmed/35520056 http://dx.doi.org/10.1039/d0ra01729a |
Ejemplares similares
-
TPGS2000-DOX Prodrug Micelles for Improving Breast Cancer Therapy
por: Tang, Lan, et al.
Publicado: (2021) -
Efficacy of PolyMPC–DOX Prodrugs in 4T1 Tumor-Bearing
Mice
por: McRae Page, Samantha, et al.
Publicado: (2014) -
PhAc-ALGP-Dox, a Novel Anticancer Prodrug with Targeted Activation and Improved Therapeutic Index
por: Casazza, Andrea, et al.
Publicado: (2022) -
Erk phosphorylation reduces the thymoquinone toxicity in human hepatocarcinoma
por: Zhang, Bin, et al.
Publicado: (2021) -
A novel doxorubicin-glucuronide prodrug DOX-GA3 for tumour-selective chemotherapy: distribution and efficacy in experimental human ovarian cancer
por: Houba, P H J, et al.
Publicado: (2001)